Anti-CD22 monoclonal antibody-saporin-6 complex

Drug Profile

Anti-CD22 monoclonal antibody-saporin-6 complex

Latest Information Update: 26 Aug 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Sep 1998 Profile reviewed
  • 26 Sep 1995 Investigation in Non-Hodgkin's lymphoma in United Kingdom (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top